Clinical Evaluation & Performance Evaluation
MDR Article 61 / Annex XIV • IVDR Article 56 / Annex XIII
Clinical evaluation (MDR) and performance evaluation (IVDR) are the scientific cornerstones of device safety. They confirm that a device achieves its intended clinical benefits while maintaining an acceptable benefit-risk profile — and they never stop. Evidence must be gathered, evaluated, and updated throughout the device's entire lifetime.
🏥 Healthcare Worker Takeaway
Why this matters to you: Every medical device and IVD you use in clinical practice has undergone (or should have undergone) a rigorous clinical or performance evaluation. When procuring devices, ask for the CER or PER — it tells you the strength of evidence behind the device. Your real-world feedback (incidents, near-misses, usability concerns) feeds directly back into this evaluation and helps manufacturers improve safety for all patients.
1MDR vs IVDR — Two Parallel Frameworks
Both regulations require robust scientific evidence — but they use different terminology and focus on different aspects because medical devices and IVDs interact with patients in fundamentally different ways.
MDR — Clinical Evaluation
- Article 61 — core requirement
- Annex XIV Part A — evaluation procedure
- Annex XIV Part B — PMCF requirements
- Output: Clinical Evaluation Report (CER)
- Focus: Direct patient contact, benefit-risk ratio
- Clinical investigations: Articles 62–82
IVDR — Performance Evaluation
- Article 56 — core requirement
- Annex XIII Part A — evaluation procedure
- Annex XIII Part B — PMPF requirements
- Output: Performance Evaluation Report (PER)
- Focus: Analytical + clinical performance, scientific validity
- Performance studies: Articles 57–77
Knowledge Check
What is the key output document of a clinical evaluation under the MDR?
2Three Sources of Clinical Data (MDR)
MDR Annex XIV Part A defines three categories of data that must be identified, appraised, and analysed within the clinical evaluation. A robust CER typically draws on all three.
Published Literature
- Systematic literature review using defined search protocol
- Peer-reviewed journals, conference proceedings
- Must cover the device, equivalent devices & state of the art
- Appraisal: weight of evidence, relevance, methodological quality
Clinical Investigation Data
- Prospective clinical studies (pre- or post-market)
- Device-specific data on safety & performance
- Must follow ISO 14155 and MDR Articles 62–82
- Gold standard for Class III / implantable devices
Other Clinical Experience
- Post-market surveillance data (complaints, incidents)
- Vigilance reports & field safety corrective actions
- Published user experience & registry data
- Real-world evidence from clinical practice
3Clinical Evaluation Report (CER) — What It Contains
The CER is a comprehensive document that demonstrates the clinical evidence supporting device safety and performance. It must be updated throughout the device lifecycle.
Device Description & Intended Purpose
Technical characteristics, intended use, target population, indications, contraindications
Benefit-Risk Analysis
Systematic evaluation of clinical benefits vs residual risks — the core conclusion of the CER
Literature Review Protocol & Results
Search strategy, databases, inclusion/exclusion criteria, data extraction, appraisal results
Clinical Investigation Summaries
Design, endpoints, patient populations, statistical methods, key results of clinical studies
Post-Market Data Analysis
Vigilance data, complaints, real-world outcomes, trend analysis from PMS activities
State of the Art Assessment
Current treatment alternatives, standard of care, benchmarking against competing technologies
Equivalence Assessment (if claimed)
Clinical, technical & biological equivalence demonstration (much stricter under MDR)
GSPR Compliance Mapping
How clinical evidence addresses each applicable General Safety & Performance Requirement
CER Update Frequency
Knowledge Check
Under the MDR, equivalence claims now require:
4Equivalence — The MDR Game-Changer
Under MDD, manufacturers could relatively easily rely on literature about similar devices. MDR Article 61(5) has dramatically changed this — making equivalence the most challenging aspect for many legacy devices.
Clinical Equivalence
- Same intended purpose
- Same clinical condition / indication
- Same target population
- Similar severity / stage of disease
- Same user (professional vs lay)
Technical Equivalence
- Similar design & specifications
- Similar conditions of use
- Similar deployment methods
- Same principles of operation
- Similar energy types / software algorithms
Biological Equivalence
- Same materials in contact with body
- Same body contact surfaces
- Similar contact duration
- Similar release characteristics
- Same biocompatibility profile
Critical MDR Restriction
For Class III and implantable devices, equivalence to a device of another manufacturer is no longer sufficient to avoid clinical investigations unless the manufacturers have a contract giving the claiming manufacturer full access to the technical documentation of the equivalent device on an ongoing basis. This effectively means most Class III / implantable devices need their own clinical investigation data.
5IVDR Performance Evaluation — The Three Pillars
IVDR Article 56 structures the performance evaluation around three interconnected pillars. All three must be addressed in the Performance Evaluation Report (PER).
Scientific Validity
Is there a well-established association between the analyte/marker and the clinical condition?
- Published scientific evidence for the biomarker/analyte
- Established clinical guidelines referencing the analyte
- State-of-the-art for the intended clinical application
- Biological plausibility of the analyte–condition association
Analytical Performance
How well does the device measure what it claims to measure?
- Sensitivity, specificity, accuracy, precision
- Measuring range & linearity
- Limit of detection & quantitation
- Interfering substances & cross-reactivity
- Reproducibility & repeatability
- Sample stability & matrix effects
Clinical Performance
Does the device produce clinically meaningful results for the intended patient population?
- Diagnostic sensitivity & specificity
- Positive & negative predictive values
- Likelihood ratios
- Expected values in target populations
- Clinical outcome impact assessment
Knowledge Check
Which of the following is NOT one of the three pillars of IVDR performance evaluation?
6Clinical Investigations & Performance Studies
When existing data is insufficient, manufacturers must conduct prospective studies. These are heavily regulated to protect study participants.
Clinical Investigation Plan (CIP)
Define objectives, endpoints, inclusion/exclusion criteria, sample size, statistical methods per ISO 14155
Ethics Committee Approval
Submit to Research Ethics Committee (REC) — in Ireland, via the National Office for Research Ethics Committees (NREC)
Competent Authority Notification
Notify HPRA at least 30 days before starting. HPRA may request modifications or object within the validation period
Informed Consent
Written informed consent from all participants. Must include risks, alternatives, data protection, and right to withdraw
Conduct the Investigation
Follow GCP principles, CIP protocol, monitor sites, ensure quality management system compliance
Safety Reporting (SAEs)
Report Serious Adverse Events (SAEs) to sponsor immediately. Sponsor reports to HPRA and ethics committee per timelines
Statistical Analysis & Report
Analyse data per pre-specified statistical analysis plan. Produce clinical investigation report per MDR Annex XV
EUDAMED Registration
Register investigation and results in EUDAMED. Summary results must be publicly available regardless of outcome
7PMCF & PMPF — Continuous Evidence Generation
Post-Market Clinical Follow-up (PMCF) under MDR and Post-Market Performance Follow-up (PMPF) under IVDR are proactive, planned processes — not afterthoughts. They feed directly back into the CER/PER and the PMS system.
PMCF (MDR Annex XIV Part B)
- ✅ Confirms ongoing safety and performance
- ✅ Identifies previously unknown risks or emerging trends
- ✅ Evaluates long-term safety and benefit-risk ratio
- ✅ Updates the CER with real-world data
- ✅ Results feed into PSUR and PMS system
PMPF (IVDR Annex XIII Part B)
- ✅ Confirms ongoing analytical and clinical performance
- ✅ Identifies new scientific validity concerns
- ✅ Detects performance degradation or interference issues
- ✅ Updates the PER with real-world data
- ✅ Results feed into PSUR and PMS system
PMCF Evaluation Report
The results of PMCF activities must be documented in a PMCF Evaluation Report that forms part of the CER. This report must be updated at least annually for higher-risk devices and must include conclusions on the need for preventive or corrective measures. The Notified Body reviews the PMCF plan and report as part of ongoing conformity assessment.
Knowledge Check
A hospital in Cork is participating in a PMCF study for a Class III orthopaedic implant. What is the hospital's primary obligation?
8Case Study — Hip Implant Clinical Evaluation Journey
Class III Total Hip Replacement — MDD to MDR Transition
An Irish-based orthopaedic device manufacturer transitions their MDD-certified total hip replacement to MDR compliance. This real-world scenario illustrates the clinical evaluation challenges.
Gap Analysis
Existing CER relied on equivalence to a competitor's device — no contract for data access. Under MDR, this equivalence route is blocked for Class III without a contract.
Literature Review Update
Expanded systematic review identifies 12 years of registry data from the National Joint Registry showing excellent survivorship but limited data on obese patients (BMI > 35).
PMCF Study Design
Multi-centre PMCF study across 4 Irish hospitals (Galway, Cork, Dublin x2) designed to generate 5-year outcomes data in the under-represented population.
HPRA & NREC Submissions
Clinical Investigation Plan submitted to HPRA (30-day validation) and NREC for ethics approval. Informed consent documents translated to Irish and Plain English.
Ongoing PMCF
Annual CER updates incorporate new registry data, PMCF interim results, and vigilance data. NB reviews updated CER at each surveillance audit.
Outcome
Full MDR compliance achieved. PMCF data confirms benefit-risk ratio remains favourable. Real-world evidence now stronger than MDD-era CER.
Key Takeaways
Irish Context — Clinical Evidence & the HPRA
The HPRA may request clinical evaluation reports from manufacturers as part of market surveillance. Hospital clinical teams may be asked to contribute post-market clinical follow-up (PMCF) data.
Clinicians in HSE facilities participating in PMCF studies should ensure these are conducted in line with the hospital research ethics framework.
This is educational content only and is not an accredited or externally verified course. Always refer to official HPRA publications and your facility's own policies.
Knowledge Check
4 questions · 80% required to pass
Q1.What is the purpose of a Clinical Evaluation Report (CER) under MDR?
Q2.Under MDR, what are the three main sources of clinical data?
Q3.What is PMCF (Post-Market Clinical Follow-up)?
Q4.What is the IVDR equivalent of the Clinical Evaluation Report?
0/4 answered
Print-Friendly Summary
One-page PDF for ward reference & quick revision
Was this module useful?